Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 953-959

  Gupta, Pankaj ^a   Leroy, Suzanne C ^a   Luikart, Sharon D ^a   Bateman, Anne ^a   Morrison, Vicki A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood transfusion; Costs and cost analysis; Myelodysplastic syndromes; Platelet transfusion

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RESOURCE MANAGEMENT; THROMBOCYTE TRANSFUSION;

BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0032843170     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00113-7     Document Type: Article

References (31)

1. Bennett J.M. Meeting highlights: therapeutic strategies and supportive care in myelodysplastic syndromes: yesterday, today and tomorrow. Leuk. Res. 22(suppl 1):1998;1.
2. Hellstrom-Lindberg E., Hast R., Radlund A., Ost A. Incidence of myelodysplastic syndrome is increasing. Careful diagnosis is necessary for choice of the treatment. Lakartidningen. 91:1994;4253.
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R. et al. The French-American-British Co-operative Group: proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189.
4. Appelbaum F.R., Anderson J. Bone marrow transplantation for myelodysplasia in adults and children: when and who? Leukemia. Res. 22(suppl 1):1998;35.
5. Weisdorf D.J., Oken M.M., Johnson G.J., Rydell R.E. Chronic myelodysplastic syndromes: short survival with or without evolution to acute leukaemia. Br. J. Haematol. 55:1983;691.
6. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59:1985;425.
7. Pomeroy C., Oken M.M., Rydell R.E., Filice G.A. Infection in the myelodysplastic syndromes. Am. J. Med. 90:1991;338.
8. Thomas M.L. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk. Res. 22(suppl 1):1998;41.
9. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89:1995;67.
10. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M. et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 92:1998;68.
11. Negrin R.S., Stein R., Doherty K., Cornwell J., Vardiman J., Krantz S. et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 87:1996;4076.
12. Rose E.H., Abels R.I., Nelson R.A., McCullough D.M., Lessin L. The use of r-HuEPO in the treatment of anaemia related to myelodysplasia (MDS). Br. J. Haematol. 89:1995;831.
13. Mittelman M., Lessin L.S. Clinical application of recombinant erythropoietin in myelodysplasia. Hematol. Oncol. Clin. North. Am. 8:1994;993.
14. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R. et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364.
15. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 90:1997;2969.
16. Gardin C., Chaibi P., de Revel T., Rousselot P., Turlure P., Miclea J.M. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia. 11:1997;16.
17. Beran M, Kantarjian H, Keating M, O'Brien S, Pierce S, Koller C, et al. Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Blood 1997;90(10 Suppl 1):583a (abstr).
18. Silverman LR, Demakos EP, Peterson B, Odchimar-Reissig R, Nelson D, Kornblith AB, et al. A randomized controlled trial of subcutaneous azacytidine (Aza C) in patients with the myelodysplastic syndrome (MDS): a study of the cancer and leukemia group B (CALGB). Proc Am Soc Clin Oncol (Los Angeles, CA), 1998;17:14a (abstr).
19. Bernstein S.H., Brunetto V.L., Davey F.R., Wurster-Hill D., Mayer R.J., Stone R.M. et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J. Clin. Oncol. 14:1996;2486.
20. Mohandas K., Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion. 35:1995;427.
21. Forbes J.M., Anderson G.F., Bleecker G.C., Rossi E.C., Moss G.S. Blood transfusion costs: a multicenter study. Transfusion. 31:1991;318.
22. Etchason J., Petz L., Keeler E., Calhoun L., Kleinman S., Snider C. et al. The cost effectiveness of preoperative autologous blood donations. N. Engl. J. Med. 332:1995;719.
23. Lubarsky D.A., Hahn C., Bennett D.H., Smith L.R., Bredehoeft S.J., Klein H.G. et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth. Analg. 79:1994;629.
24. Sheffield R.E., Sullivan S.D., Saltiel E., Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann. Pharmacother. 31:1997;15.
25. Friedberg R.C. Clinical and laboratory factors underlying refractoriness to platelet transfusions. J. Clin. Apheresis. 11:1996;143.
26. Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Semin. Oncol. 1994;21(2 suppl. 3):29.
27. National Institutes of Health Consensus Development Conference. Perioperative red cell transfusion. Transfus Med Rev 1989;3:63.
28. Walker R.H. Special report: transfusion risks. Am. J. Clin. Pathol. 88:1987;374.
29. Issitt P.D. Applied blood group serology. 1985;477 Montgomery Scientific Publications, Miami.
30. Kanda Y., Tanaka Y., Kami M., Saito T., Asai T., Izutsu K. et al. TT virus in bone marrow transplant recipients. Blood. 93:1999;2485.
31. Hellstrom-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J. et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99:1997;344.